scholarly journals HER2-L755S mutation induces hyperactive MAPK and PI3K-mTOR signaling, leading to resistance to HER2 tyrosine kinase inhibitor treatment

Cell Cycle ◽  
2019 ◽  
Vol 18 (13) ◽  
pp. 1513-1522 ◽  
Author(s):  
Jiayao Li ◽  
Qian Xiao ◽  
Yi Bao ◽  
Wenyu Wang ◽  
Jianyuan Goh ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Kinase Inhibitor ◽  
Mtor Signaling ◽  
Inhibitor Treatment ◽  
Her2 Tyrosine Kinase Inhibitor

PS-121 Model for advising on interactions and adverse reactions of tyrosine kinase inhibitor treatment

2015 ◽  
Vol 22 (Suppl 1) ◽  
pp. A184.1-A184
Author(s):  
R Gazquez Perez ◽  
A Garcia Bonilla ◽  
R Gavira Moreno ◽  
J Sierra Sanchez ◽  
V Gonzalez Rosa ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Adverse Reactions ◽  
Kinase Inhibitor ◽  
Inhibitor Treatment

scholarly journals Targeting PRMT1-mediated FLT3 methylation disrupts maintenance of MLL-rearranged acute lymphoblastic leukemia

Blood ◽  
2019 ◽  
Vol 134 (15) ◽  
pp. 1257-1268 ◽  
Author(s):  
Yinghui Zhu ◽  
Xin He ◽  
Yi-Chun Lin ◽  
Haojie Dong ◽  
Lei Zhang ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Tyrosine Kinase ◽  
Cell Survival ◽  
Tyrosine Kinase Inhibitor ◽  
Kinase Inhibitor ◽  
Lymphoblastic Leukemia ◽  
Key Points ◽  
Survival And Growth ◽  
Inhibitor Treatment

Key Points High PRMT1 expression maintains MLL-r ALL cell survival and growth by regulating FLT3 methylation at R972/973. PRMT1 inhibition enhances ablation of MLL-r ALL by tyrosine kinase inhibitor treatment.

Sign in / Sign up

Export Citation Format

Share Document